vorinostat has been researched along with Kidney Neoplasms in 14 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Kidney Neoplasms: Tumors or cancers of the KIDNEY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat was administered at 300 mg orally twice daily in combination with escalating doses of isotretinoin for 3 consecutive days per week." | 2.94 | NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. ( Christos, P; Dutcher, JP; Gudas, LJ; Molina, AM; Nanus, DM; Tagawa, ST; Thomas, C; van der Mijn, JC; Wright, J, 2020) |
| " Dosing was limited by thrombocytopenia." | 2.80 | Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. ( Corrigan, A; Denlinger, CS; Devarajan, K; Malizzia, L; Olszanski, AJ; Plimack, ER; Roethke, SK; Tetzlaff, CH; Wong, YN; Zibelman, M, 2015) |
| "Vorinostat is a histone deacetylase inhibitor approved for cancer treatment, but it could attenuate its anticancer activity by activating the mTOR pathway." | 1.56 | Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells. ( Asano, T; Isono, M; Miyai, K; Okubo, K; Sato, A, 2020) |
| "Vorinostat was considered as the most promising drug for detailed discussion." | 1.51 | The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets. ( Chen, G; Li, SH; Li, ZK; Lin, P; Pang, JS; Wang, XD; Yan, HB, 2019) |
| " Mechanistically, SAHA combined with bortezomib enhanced protein ubiquitination synergistically and enhanced histone acetylation by inhibiting the expression of HDACs." | 1.38 | Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. ( Asano, T; Ito, K; Sato, A; Sumitomo, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Okubo, K | 1 |
| Isono, M | 1 |
| Miyai, K | 1 |
| Asano, T | 7 |
| Sato, A | 4 |
| Molina, AM | 1 |
| van der Mijn, JC | 1 |
| Christos, P | 1 |
| Wright, J | 1 |
| Thomas, C | 1 |
| Dutcher, JP | 1 |
| Nanus, DM | 1 |
| Tagawa, ST | 1 |
| Gudas, LJ | 1 |
| Pang, JS | 1 |
| Li, ZK | 1 |
| Lin, P | 1 |
| Wang, XD | 1 |
| Chen, G | 1 |
| Yan, HB | 1 |
| Li, SH | 1 |
| Zhu, Q | 1 |
| Yu, L | 1 |
| Qin, Z | 1 |
| Chen, L | 1 |
| Hu, H | 1 |
| Zheng, X | 1 |
| Zeng, S | 1 |
| Schiffgen, M | 1 |
| Schmidt, DH | 1 |
| von Rücker, A | 1 |
| Müller, SC | 1 |
| Ellinger, J | 1 |
| Zibelman, M | 1 |
| Wong, YN | 1 |
| Devarajan, K | 1 |
| Malizzia, L | 1 |
| Corrigan, A | 1 |
| Olszanski, AJ | 1 |
| Denlinger, CS | 1 |
| Roethke, SK | 1 |
| Tetzlaff, CH | 1 |
| Plimack, ER | 1 |
| Pili, R | 1 |
| Liu, G | 1 |
| Chintala, S | 1 |
| Verheul, H | 1 |
| Rehman, S | 1 |
| Attwood, K | 1 |
| Lodge, MA | 1 |
| Wahl, R | 1 |
| Martin, JI | 1 |
| Miles, KM | 1 |
| Paesante, S | 1 |
| Adelaiye, R | 1 |
| Godoy, A | 1 |
| King, S | 1 |
| Zwiebel, J | 1 |
| Carducci, MA | 1 |
| Mahalingam, D | 1 |
| Medina, EC | 1 |
| Esquivel, JA | 1 |
| Espitia, CM | 1 |
| Smith, S | 1 |
| Oberheu, K | 1 |
| Swords, R | 1 |
| Kelly, KR | 1 |
| Mita, MM | 1 |
| Mita, AC | 1 |
| Carew, JS | 1 |
| Giles, FJ | 1 |
| Nawrocki, ST | 1 |
| Horiguchi, A | 2 |
| Ito, K | 3 |
| Sumitomo, M | 3 |
| Dasari, A | 1 |
| Gore, L | 1 |
| Messersmith, WA | 1 |
| Diab, S | 1 |
| Jimeno, A | 1 |
| Weekes, CD | 1 |
| Lewis, KD | 1 |
| Drabkin, HA | 1 |
| Flaig, TW | 1 |
| Camidge, DR | 1 |
| Kim, MJ | 1 |
| Kim, DE | 1 |
| Jeong, IG | 1 |
| Choi, J | 1 |
| Jang, S | 1 |
| Lee, JH | 1 |
| Ro, S | 1 |
| Hwang, JJ | 1 |
| Kim, CS | 1 |
| Gray, SG | 1 |
| Qian, CN | 1 |
| Furge, K | 1 |
| Guo, X | 1 |
| Teh, BT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)[NCT01169532] | Phase 1 | 16 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Kaplan Meier curves will be used. Proportions, 95% confidence intervals, and cumulative incidence curves will be used to characterize response rates. (NCT01169532)
Timeframe: 1 year
| Intervention | weeks (Median) |
|---|---|
| Treatment (Ridaforolimus and Vorinostat) | 40.7 |
Kaplan Meier curves will be used. Proportions, 95% confidence intervals, and cumulative incidence curves will be used to characterize response rates. (NCT01169532)
Timeframe: 1 year
| Intervention | weeks (Median) |
|---|---|
| Treatment (Ridaforolimus and Vorinostat) | 17.1 |
MTD denoted as the highest dose at which no more than one of six patients experienced a dose limiting toxicity (DLT), and expanded to a total of 12 patients. Any drug-related grade 3 or 4 toxicity occurring during the first three weeks of treatment (except nausea, vomiting, diarrhea, serum lipid elevation, or transient electrolyte abnormality that resolved to a grade of 0-2 with medical management) was considered a dose limiting toxicity (DLT). Assessed by National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 4.0. (NCT01169532)
Timeframe: First 3 weeks of treatment
| Intervention | milligrams (Number) | |
|---|---|---|
| Ridaforolimus qd days 1-5 every week | Vorinostat bid days 1-3 every week | |
| Treatment (Ridaforolimus and Vorinostat) | 20 | 100 |
4 trials available for vorinostat and Kidney Neoplasms
| Article | Year |
|---|---|
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2020 |
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Dose | 2015 |
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2017 |
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 2013 |
10 other studies available for vorinostat and Kidney Neoplasms
| Article | Year |
|---|---|
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Prolife | 2020 |
The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Computational Biology; Gene Express | 2019 |
Regulation of
Topics: Acetylation; Carcinoma, Renal Cell; Cell Line, Tumor; Decitabine; Down-Regulation; Drug Resistance, | 2019 |
Epigenetic regulation of microRNA expression in renal cell carcinoma.
Topics: Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; | 2013 |
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcino | 2010 |
Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Drug Therapy, Combination; HIV Protease Inh | 2010 |
Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proli | 2011 |
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Topics: Acetylation; Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boron | 2012 |
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferatio | 2012 |
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines.
Topics: Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Enzyme Inhibitors; Gene Expression Profiling; Gene | 2004 |